Vanda Pharmaceuticals Inc (VNDA) Implied Volatility Current

Tracking VNDA implied volatility helps you identify when options premiums on Vanda Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Vanda Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when VNDA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Vanda Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For VNDA, tracking metrics like VNDA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on VNDA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness.

The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where VNDA implied volatility sits today versus where it has been. Our scanner ranks Vanda Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in VNDA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Vanda Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.